Preventive, Diagnostic and Therapeutic Applications of Baculovirus Expression Vector System

  • Neeraj Kumar
  • Deepak Pandey
  • Ashutosh Halder


Different strategies are being worked out for engineering the original baculovirus expression vector (BEV) system to produce cost-effective clinical biologics at commercial scale. To date, thousands of highly variable molecules in the form of heterologous proteins, virus-like particles, surface display proteins/antigen carriers, heterologous viral vectors and gene delivery vehicles have been produced using this system. These products are being used in vaccine production, tissue engineering, stem cell transduction, viral vector production, gene therapy, cancer treatment and development of biosensors. Recombinant proteins that are expressed and post-translationally modified using this system are also suitable for functional, crystallographic studies, microarray and drug discovery-based applications. Till now, four BEV-based commercial products (Cervarix®, Provenge®, Glybera® and Flublok®) have been approved for humans, and myriad of others are in different stages of preclinical or clinical trials. Five products (Porcilis® Pesti, BAYOVAC CSF E2®, Circumvent® PCV, Ingelvac CircoFLEX® and Porcilis® PCV) got approval for veterinary use, and many more are in the pipeline. In the present chapter, we have emphasized on both approved and other baculovirus-based products produced in insect cells or larvae that are important from clinical perspective and are being developed as preventive, diagnostic or therapeutic agents. Further, the potential of recombinant adeno-associated virus (rAAV) as gene delivery vector has been described. This system, due to its relatively extended gene expression, lack of pathogenicity and the ability to transduce a wide variety of cells, gained extensive popularity just after the approval of first AAV-based gene therapy drug alipogene tiparvovec (Glybera®). Numerous products based on AAV which are presently in different clinical trials have also been highlighted.


Baculovirus expression system Insect Virus-like particles Vaccine Protein Gene therapy 


  1. Airenne KJ et al (2013) Baculovirus: an insect-derived vector for diverse gene transfer applications. Mol Ther 21(4):739–749PubMedPubMedCentralCrossRefGoogle Scholar
  2. Ang WX et al (2016) Local immune stimulation by intravesical instillation of baculovirus to enable bladder cancer therapy. Sci Rep 6:27455PubMedPubMedCentralCrossRefGoogle Scholar
  3. Atmar RL et al (2011) Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med 365(23):2178–2187PubMedPubMedCentralCrossRefGoogle Scholar
  4. Aucoin MG et al (2007) Virus-like particle and viral vector production using the baculovirus expression vector system/insect cell system. In: Baculovirus and Insect Cell Expression Protocols. Humana, New York, pp 281–296Google Scholar
  5. Bakay RA et al (2007) Analyses of a phase 1 clinical trial of adeno-associated virus-nerve growth factor (CERE-110) gene therapy in Alzheimer’s disease: 866. Neurosurgery 61(1):216CrossRefGoogle Scholar
  6. Ball JM et al (1999) Recombinant Norwalk virus–like particles given orally to volunteers: phase I study. Gastroenterology 117(1):40–48PubMedCrossRefGoogle Scholar
  7. Barber GN, Clegg J, Lloyd G (1990) Expression of the Lassa virus nucleocapsid protein in insect cells infected with a recombinant baculovirus: application to diagnostic assays for Lassa virus infection. J Gen Virol 71(1):19–28PubMedCrossRefGoogle Scholar
  8. Barnett J et al (1990) Human β nerve growth factor obtained from a baculovirus expression system has potent in vitro and in vivo neurotrophic activity. Exp Neurol 110(1):11–24PubMedCrossRefGoogle Scholar
  9. Burke RL (1999) Herpes simplex virus diagnostics. Google PatentsGoogle Scholar
  10. Chen H-C et al (2008) Combination of baculovirus-expressed BMP-2 and rotating-shaft bioreactor culture synergistically enhances cartilage formation. Gene Ther 15(4):309–317PubMedCrossRefGoogle Scholar
  11. Choi K-S et al (2014) Baculovirus expression of the avian paramyxovirus 2 HN gene for diagnostic applications. J Virol Methods 198:12–17PubMedCrossRefGoogle Scholar
  12. Chuang C-K et al (2009) Xenotransplantation of human mesenchymal stem cells into immunocompetent rats for calvarial bone repair. Tissue Eng A 16(2):479–488CrossRefGoogle Scholar
  13. Chung C-Y et al (2010) Enterovirus 71 virus-like particle vaccine: improved production conditions for enhanced yield. Vaccine 28(43):6951–6957PubMedCrossRefGoogle Scholar
  14. Cox MM, Hashimoto Y (2011) A fast track influenza virus vaccine produced in insect cells. J Invertebr Pathol 107:S31–S41PubMedCrossRefGoogle Scholar
  15. Day TP et al (2014) Advances in AAV vector development for gene therapy in the retina. In: Retinal degenerative diseases. Springer, New York, pp 687–693CrossRefGoogle Scholar
  16. de Diego ACP et al (2011) Characterization of protection afforded by a bivalent virus-like particle vaccine against bluetongue virus serotypes 1 and 4 in sheep. PLoS One 6(10):e26666CrossRefGoogle Scholar
  17. Desrosiers R et al (2009) Use of a one-dose subunit vaccine to prevent losses associated with porcine circovirus type 2. J Swine Health Prod 17(3):148–154Google Scholar
  18. dos Santos CND et al (1992) Trypanosoma cruzi flagellar repetitive antigen expression by recombinant baculovirus: towards an improved diagnostic reagent for Chagas’ disease. Biotechnology 10:1474–1477PubMedGoogle Scholar
  19. Dudognon B et al (2014) Production of functional active human growth factors in insects used as living biofactories. J Biotechnol 184:229–239PubMedCrossRefGoogle Scholar
  20. Eshaghi M et al (2004) Nipah virus glycoprotein: production in baculovirus and application in diagnosis. Virus Res 106(1):71–76PubMedCrossRefGoogle Scholar
  21. Fauquet CM et al (2005) Virus taxonomy: VIIIth report of the International Committee on Taxonomy of Viruses. Academic, LondonGoogle Scholar
  22. Felberbaum RS (2015) The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors. Biotechnol J 10(5):702–714PubMedCrossRefGoogle Scholar
  23. French T, Marshall J, Roy P (1990) Assembly of double-shelled, viruslike particles of bluetongue virus by the simultaneous expression of four structural proteins. J Virol 64(12):5695–5700PubMedPubMedCentralGoogle Scholar
  24. Frey S, Treanor JJ, Atmar RL, Topman D, Chen WH, Ferreira J (2011) Phase 1 dosage escalation, safety and immunogenicity study of a bivalent norovirus VLP vaccine by the intramuscular route. In Annual meeting of the infectious diseases society of America, Boston, 2011Google Scholar
  25. Gaudet D et al (2010) Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency. Atheroscler Suppl 11(1):55–60PubMedCrossRefGoogle Scholar
  26. Gil F et al (2011) Targeting antigens to an invariant epitope of the MHC Class II DR molecule potentiates the immune response to subunit vaccines. Virus Res 155(1):55–60PubMedCrossRefGoogle Scholar
  27. Goldman B, DeFrancesco L (2009) The cancer vaccine roller coaster. Nat Biotechnol 27(2):129–139PubMedCrossRefGoogle Scholar
  28. Gómez-Sebastián S et al (2012) Rotavirus A-specific single-domain antibodies produced in baculovirus-infected insect larvae are protective in vivo. BMC Biotechnol 12(1):59PubMedPubMedCentralCrossRefGoogle Scholar
  29. Guyre P et al (2002) Recombinant cat allergen, Fel dI, expressed in baculovirus for diagnosis and treatment of cat allergy. Google PatentsGoogle Scholar
  30. High K et al (2014) Current status of haemophilia gene therapy. Haemophilia 20(s4):43–49PubMedCrossRefGoogle Scholar
  31. Hu YC, Bentley WE (2001) Effect of MOI ratio on the composition and yield of chimeric infectious bursal disease virus-like particles by baculovirus co-infection: Deterministic predictions and experimental results. Biotechnol Bioeng 75(1):104–119PubMedCrossRefGoogle Scholar
  32. Janson C et al (2002) Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum Gene Ther 13(11):1391–1412PubMedCrossRefGoogle Scholar
  33. Jarmin S et al (2014) New developments in the use of gene therapy to treat Duchenne muscular dystrophy. Expert Opin Biol Ther 14(2):209–230PubMedCrossRefGoogle Scholar
  34. Jiang X et al (1992) Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J Virol 66(11):6527–6532PubMedPubMedCentralGoogle Scholar
  35. Jiang X et al (1998) Baculovirus-expressed Sapporo-like calicivirus capsid self-assembles into virus-like particles (VLPs) and can be used to detect antibody in children† 854. Pediatr Res 43:148–148Google Scholar
  36. Jiang X et al (2000) Diagnosis of human caliciviruses by use of enzyme immunoassays. J Infect Dis 181(Supplement 2):S349–S359PubMedCrossRefGoogle Scholar
  37. Kanesashi S-N et al (2003) Simian virus 40 VP1 capsid protein forms polymorphic assemblies in vitro. J Gen Virol 84(7):1899–1905PubMedCrossRefGoogle Scholar
  38. Kantoff PW et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5):411–422PubMedCrossRefGoogle Scholar
  39. Kaplitt MG et al (2007) Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, phase I trial. Lancet 369(9579):2097–2105PubMedCrossRefGoogle Scholar
  40. King AM et al (2011) Virus taxonomy: ninth report of the International Committee on Taxonomy of Viruses. Elsevier, LondonGoogle Scholar
  41. Ko Y-J et al (2005) Noninfectious virus-like particle antigen for detection of swine vesicular disease virus antibodies in pigs by enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 12(8):922–929PubMedPubMedCentralGoogle Scholar
  42. Ko Y-J et al (2010) Use of a baculovirus-expressed structural protein for the detection of antibodies to foot-and-mouth disease virus type A by a blocking enzyme-linked immunosorbent assay. Clin Vaccine Immunol 17(1):194–198PubMedCrossRefGoogle Scholar
  43. Kong XG et al (1997) Application of equine infectious anemia virus core proteins produced in a baculovirus expression system to serological diagnosis. Microbiol Immunol 41(12):975–980PubMedCrossRefGoogle Scholar
  44. Kost TA, Condreay JP (2002) Innovations—biotechnology: baculovirus vectors as gene transfer vectors for mammalian cells: biosafety considerations. Appl Biosaf 7(3):167–169CrossRefGoogle Scholar
  45. Kotin RM et al (1991) Mapping and direct visualization of a region-specific viral DNA integration site on chromosome 19q13-qter. Genomics 10(3):831–834PubMedCrossRefGoogle Scholar
  46. Krammer F et al (2010) Trichoplusia ni cells (High FiveTM) are highly efficient for the production of influenza A virus-like particles: a comparison of two insect cell lines as production platforms for influenza vaccines. Mol Biotechnol 45(3):226–234PubMedPubMedCentralCrossRefGoogle Scholar
  47. Laurent S et al (1994) Recombinant rabbit hemorrhagic disease virus capsid protein expressed in baculovirus self-assembles into viruslike particles and induces protection. J Virol 68(10):6794–6798PubMedPubMedCentralGoogle Scholar
  48. Lee JH et al (2014) Expression of recombinant anti-breast cancer immunotherapeutic monoclonal antibody in baculovirus–insect cell system. Entomol Res 44(5):207–214CrossRefGoogle Scholar
  49. Liu L-J et al (2008) Efficient production of type 2 porcine circovirus-like particles by a recombinant baculovirus. Arch Virol 153(12):2291–2295PubMedCrossRefGoogle Scholar
  50. Liu T et al (2015) Production of a fragment of glycoprotein G of herpes simplex virus type 2 and evaluation of its diagnostic potential. Singap Med J 56(6):346CrossRefGoogle Scholar
  51. Long G et al (2006) Functional entry of baculovirus into insect and mammalian cells is dependent on clathrin-mediated endocytosis. J Virol 80(17):8830–8833PubMedPubMedCentralCrossRefGoogle Scholar
  52. López-Macías C et al (2011) Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine 29(44):7826–7834PubMedCrossRefGoogle Scholar
  53. Luckow VA, Summers MD (1988) Trends in the development of baculovirus expression vectors. Nat Biotechnol 6(1):47–55CrossRefGoogle Scholar
  54. Luo W et al (2011) Baculovirus vectors for antiangiogenesis-based cancer gene therapy. Cancer Gene Ther 18(9):637–645PubMedCrossRefGoogle Scholar
  55. Luo W et al (2012) Development of the hybrid Sleeping Beauty-baculovirus vector for sustained gene expression and cancer therapy. Gene Ther 19(8):844–851PubMedCrossRefGoogle Scholar
  56. MacLachlan TK et al (2011) Preclinical safety evaluation of AAV2-sFLT01—a gene therapy for age-related macular degeneration. Mol Ther 19(2):326–334PubMedCrossRefGoogle Scholar
  57. Maranga L et al (2002) Large scale production and downstream processing of a recombinant porcine parvovirus vaccine. Appl Microbiol Biotechnol 59(1):45–50PubMedCrossRefGoogle Scholar
  58. Marks WJ et al (2010) Gene delivery of AAV2-neurturin for Parkinson’s disease: a double-blind, randomised, controlled trial. Lancet Neurol 9(12):1164–1172PubMedCrossRefGoogle Scholar
  59. Marx F et al (2001) Diagnostic immunoassays for tick-borne encephalitis virus based on recombinant baculovirus protein expression. J Virol Methods 91(1):75–84PubMedCrossRefGoogle Scholar
  60. Mathavan S et al (1995) High-level production of human parathyroid hormone in Bombyx mori larvae and BmN cells using recombinant baculovirus. Gene 167(1):33–39PubMedCrossRefGoogle Scholar
  61. Mauch L et al (1993) Baculovirus-mediated expression of human 65 kDa and 67 kDa glutamic acid decarboxylases in SF9 insect cells and their relevance in diagnosis of insulin-dependent diabetes mellitus. J Biochem 113(6):699–704PubMedCrossRefGoogle Scholar
  62. Mazur NI et al (2015) Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics. Lancet Respir Med 3(11):888–900PubMedCrossRefGoogle Scholar
  63. Mecham J, Wilson W (2004) Antigen capture competitive enzyme-linked immunosorbent assays using baculovirus-expressed antigens for diagnosis of bluetongue virus and epizootic hemorrhagic disease virus. J Clin Microbiol 42(2):518–523PubMedPubMedCentralCrossRefGoogle Scholar
  64. Mena JA et al (2010) Improving adeno-associated vector yield in high density insect cell cultures. J Gene Med 12(2):157–167PubMedCrossRefGoogle Scholar
  65. Monie A et al (2008) Cervarix™: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biol Targets Ther 2(1):107–113Google Scholar
  66. Montross L et al (1991) Nuclear assembly of polyomavirus capsids in insect cells expressing the major capsid protein VP1. J Virol 65(9):4991–4998PubMedPubMedCentralGoogle Scholar
  67. Moormann RJ et al (2000) Development of a classical swine fever subunit marker vaccine and companion diagnostic test. Vet Microbiol 73(2):209–219PubMedCrossRefGoogle Scholar
  68. Mortola E, Roy P (2004) Efficient assembly and release of SARS coronavirus-like particles by a heterologous expression system. FEBS Lett 576(1-2):174–178PubMedCrossRefGoogle Scholar
  69. Neuzil KM (2016) Progress toward a respiratory syncytial virus vaccine. Clin Vaccine Immunol 23(3):186–188PubMedPubMedCentralCrossRefGoogle Scholar
  70. O’Reilly DR, Miller LK, Luckow VA (1994) Baculovirus expression vectors: a laboratory manual. Oxford University Press on Demand, New YorkGoogle Scholar
  71. Osman AA et al (2002) Production of recombinant human tissue transglutaminase using the baculovirus expression system, and its application for serological diagnosis of coeliac disease. Eur J Gastroenterol Hepatol 14(11):1217–1223PubMedCrossRefGoogle Scholar
  72. Park D-Y et al (2011) Optimization of expression conditions for production of anti-colorectal cancer monoclonal antibody CO17-1A in baculovirus-insect cell system. Hybridoma 30(5):419–426PubMedCrossRefGoogle Scholar
  73. Pastey MK, Samal SK (1998) Baculovirus expression of the fusion protein gene of bovine respiratory syncytial virus and utility of the recombinant protein in a diagnostic enzyme immunoassay. J Clin Microbiol 36(4):1105–1108PubMedPubMedCentralGoogle Scholar
  74. Paton D et al (1991) An ELISA detecting antibody to conserved pestivirus epitopes. J Virol Methods 31(2-3):315–324PubMedCrossRefGoogle Scholar
  75. Perelygina L et al (2005) Production of herpes B virus recombinant glycoproteins and evaluation of their diagnostic potential. J Clin Microbiol 43(2):620–628PubMedPubMedCentralCrossRefGoogle Scholar
  76. Pham M-Q et al (1999) Human interleukin-2 production in insect (Trichoplusia ni) larvae: effects and partial control of proteolysis. Biotechnol Bioeng 62(2):175–182PubMedCrossRefGoogle Scholar
  77. Pillay S et al (2009) Optimization of chimeric HIV-1 virus-like particle production in a baculovirus-insect cell expression system. Biotechnol Prog 25(4):1153–1160PubMedCrossRefGoogle Scholar
  78. Prel A, Le Gall-Recule G, Jestin V (2008) Achievement of avian influenza virus-like particles that could be used as a subunit vaccine against low-pathogenic avian influenza strains in ducks. Avian Pathol 37(5):513–520PubMedCrossRefGoogle Scholar
  79. Reed JC et al (1992) A strategy for generating monoclonal antibodies against recombinant baculovirus-produced proteins: application to the Bcl-2 oncoprotein. Anal Biochem 205(1):70–76PubMedCrossRefGoogle Scholar
  80. Rocha-Zavaleta L et al (1997) Differences in serological IgA responses to recombinant baculovirus-derived human papillomavirus E2 protein in the natural history of cervical neoplasia. Br J Cancer 75(8):1144PubMedPubMedCentralCrossRefGoogle Scholar
  81. Roldão A et al (2010) Virus-like particles in vaccine development. Expert Rev Vaccines 9(10):1149–1176PubMedCrossRefGoogle Scholar
  82. Roy P, Noad R (2008) Virus-like particles as a vaccine delivery system: Myths and facts. Hum Vaccin 4(1):5–12PubMedCrossRefGoogle Scholar
  83. Saijo M et al (2007) Development of recombinant nucleoprotein-based diagnostic systems for Lassa fever. Clin Vaccine Immunol 14(9):1182–1189PubMedPubMedCentralCrossRefGoogle Scholar
  84. Seppänen H et al (1991) Diagnostic potential of baculovirus-expressed rubella virus envelope proteins. J Clin Microbiol 29(9):1877–1882PubMedPubMedCentralGoogle Scholar
  85. Sguazza GH et al (2013) Expression of the hemagglutinin HA1 subunit of the equine influenza virus using a baculovirus expression system. Rev Argent Microbiol 45(4):222–228PubMedGoogle Scholar
  86. Shi X et al (1996) Expression of biologically active human granulocyte-macrophage colony-stimulating factor in the silkworm (Bombyx mori). Biotechnol Appl Biochem 24(3):245–249PubMedGoogle Scholar
  87. Simonelli F et al (2010) Gene therapy for Leber’s congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 18(3):643–650PubMedCrossRefGoogle Scholar
  88. Smith GE, Summers M, Fraser M (1983) Production of human beta interferon in insect cells infected with a baculovirus expression vector. Mol Cell Biol 3(12):2156–2165PubMedPubMedCentralCrossRefGoogle Scholar
  89. Sugiura T et al (2001) Serological diagnosis of equine influenza using the hemagglutinin protein produced in a baculovirus expression system. J Virol Methods 98(1):1–8PubMedCrossRefGoogle Scholar
  90. Sumathy S, Palhan VB, Gopinathan KP (1996) Expression of human growth hormone in silkworm larvae through recombinant Bombyx mori nuclear polyhedrosis virus. Protein Expr Purif 7(3):262–268PubMedCrossRefGoogle Scholar
  91. Summers MD (2006) Milestones leading to the genetic engineering of baculoviruses as expression vector systems and viral pesticides. Adv Virus Res 68:3–73PubMedCrossRefGoogle Scholar
  92. Sun Y et al (2009) Protection against lethal challenge by Ebola virus-like particles produced in insect cells. Virology 383(1):12–21PubMedCrossRefGoogle Scholar
  93. van Oers MM, Pijlman GP, Vlak JM (2015) Thirty years of baculovirus–insect cell protein expression: from dark horse to mainstream technology. J Gen Virol 96(1):6–23PubMedCrossRefGoogle Scholar
  94. Van Rijn P et al (1996) Classical swine fever virus (CSFV) envelope glycoprotein E2 containing one structural antigenic unit protects pigs from lethal CSFV challenge. J Gen Virol 77(11):2737–2745PubMedCrossRefGoogle Scholar
  95. Virag T, Cecchini S, Kotin RM (2009) Producing recombinant adeno-associated virus in foster cells: overcoming production limitations using a baculovirus–insect cell expression strategy. Hum Gene Ther 28(8):807–817CrossRefGoogle Scholar
  96. Wagner R et al (1996) Safety and immunogenicity of recombinant human immunodeficiency virus-like particles in rodents and rhesus macaques. Intervirology 39(1-2):93–103PubMedCrossRefGoogle Scholar
  97. Wald A, Ashley-Morrow R (2002) Serological testing for herpes simplex virus (HSV)–1 and HSV-2 infection. Clin Infect Dis 35(Supplement 2):S173–S182PubMedCrossRefGoogle Scholar
  98. Wan C-H et al (1995) Expression of Sendai virus nucleocapsid protein in a baculovirus expression system and application to diagnostic assays for Sendai virus infection. J Clin Microbiol 33(8):2007–2011PubMedPubMedCentralGoogle Scholar
  99. Wang S, Balasundaram G (2010) Potential cancer gene therapy by baculoviral transduction. Curr Gene Ther 10(3):214–225PubMedCrossRefGoogle Scholar
  100. Weyer U, Possee RD (1991) A baculovirus dual expression vector derived from the Autographa californica nuclear polyhedrosis virus polyhedrin and p10 promoters: co-expression of two influenza virus genes in insect cells. J Gen Virol 72(12):2967–2974PubMedCrossRefGoogle Scholar
  101. Yamaji H (2014) Suitability and perspectives on using recombinant insect cells for the production of virus-like particles. Appl Microbiol Biotechnol 98(5):1963–1970PubMedCrossRefGoogle Scholar
  102. Yamshchikov GV et al (1995) Assembly of SIV virus-like particles containing envelope proteins using a baculovirus expression system. Virology 214(1):50–58PubMedCrossRefGoogle Scholar
  103. Yin X et al (2013) Detection of specific antibodies against Tembusu virus in ducks by use of an E protein-based enzyme-linked immunosorbent assay. J Clin Microbiol 51(7):2400–2402PubMedPubMedCentralCrossRefGoogle Scholar
  104. Yoshimatsu K, Arikawa J, Kariwa H (1993) Application of a recombinant baculovirus expressing hantavirus nucleocapsid protein as a diagnostic antigen in IFA test: cross reactivities among 3 serotypes of hantavirus which causes hemorrhagic fever with renal syndrome (HFRS). J Vet Med Sci 55(6):1047–1050PubMedCrossRefGoogle Scholar
  105. Zhao Y et al (2012) Targeted suicide gene therapy for glioma using human embryonic stem cell-derived neural stem cells genetically modified by baculoviral vectors. Gene Ther 19(2):189–200PubMedCrossRefGoogle Scholar
  106. Zielonka A et al (2006) Generation of virus-like particles consisting of the major capsid protein VP1 of goose hemorrhagic polyomavirus and their application in serological tests. Virus Res 120(1):128–137PubMedCrossRefGoogle Scholar
  107. Zincarelli C et al (2008) Analysis of AAV serotypes 1–9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 16(6):1073–1080PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Reproductive BiologyAll India Institute of Medical SciencesNew DelhiIndia

Personalised recommendations